reason report
lower near-term estim oral solid morgantown
pt
bottom line lower estim reflect near-term
headwind observ iqvia data like due product discontinu
morgantown oral solid dose facil carri
remedi work lower pt
believ commodit portfolio remain pressur
near term believ larg understood reflect
consensu number pull-back sinc late
compani receiv warn letter believ
larg reflect stock current level trade
ev/ebitda multipl vs gx comp even though per
estim total compani ebitda come higher
multipl brand consum cx /otc segment peer
trade respect see valu name due
pipelin includ biosimilar complex gener yupelri
growth outlook sale ep reiter
chang estim valuat acknowledg
difficult quantifi contribut morgantown specif
estim headwind vs reason
lower gx base biz sale reflect
impact move gx advair launch late
updat latest iqvia trend overal chang lower
revenu ep
final better reflect believ normal
oper busi move valuat window look
sotp weight averag multipl in-lin comp
valu ebitda yield new pt
vs previous preview note also includ chang
estim sale headwind due
remedi work morgantown facil morgantown plant
oral solid dosag osd facil look iqvia
sale data total us osd portfolio found y/i
sale declin steadili juli april
thereaft declin acceler reach
assum level y/i declin remain steadi result
y/i sale declin vs impli normal
volum declin see slide insid detail result
lower us gener sale specif bring
total impact
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
provid littl guidanc volum recoveri
assum recoveri maximum recoveri
revis estim assum y/i sale declin
us oral solid dosag portfolio assum
improv eros rate throughout rest year
last week manag indic hope get back track
normalci sometim year less optimist
achiev quickli remain seen capac level
new normal believ ramp
origin capac reason assumpt yield
improv outer year vs prior estim one
believ realist previou estim essenti impli
capac lost would recov
acknowledg limit analysi project
osd sale believ revis estim reason
note limit analysi includ inher difficulti
translat iqvia data actual sale magnitud y/i declin
us oral solid may still downsid fraction
dosag form us morgantown may equal sale
fraction said new na busi estim
least street believ taken
appropri conserv approach level eros could
come morgantown
bodi note includ explan estim
impact morgantown page
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
remedi morgantown facil may take longer allevi reach lower capac
current estim
chang model
sinc oral solid portfolio seen acceler declin
new estim assum y/i declin rate improv
iqvia data indic oral solid portfolio seen acceler declin may
y/i chang iqvia sale
appear morgantown
facil increment acceler
eros seen us oral solid
portfolio april
remain
part
chang
level
assum y/i chang
next month
hold
chang iqvia sale
chang model
translat stabl sale trajectori headwind
product discontinu eas
mylan oral solid iqvia sale actual estim
chang model
estim morgantown manufactur issu yield y/i
declin
calcul estim sale declin relat morgantown issu
actual oral solid iqvia sale
estim oral solid iqvia sale
encompass us oral solid dose
assum y/i declin reach steadi
state dec
declin flat roughli
absolut declin iqvia sale vs
estim declin actual sale
use iqvia captur rate seen
ltm
declin actual sale due morgantown issu
estim morgantown contribut
us osd dose
medicin sold us came
adjust model reflect
headwind sale
chang model
new estim consensu averag believ
taken appropri conserv approach level eros morgantown
waterfal chart sale estim chang na busi
add y/i declin
assum resum sale
worth discontinu impact sale vs believ reason
svb leerink sale estim mylan us oral solid dosag portfolio
estim total impact
morgantown issu vs
assum mylan
resum sale
product
discontinu
assum mylan
resum sale
product
discontinu
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
